A simplified, rapid and inexpensive extraction procedure for the determinaticn of the antiarrhythmic drug disopyramide and its main mctabolitc mono-N-dcsalkylated disopyramidc in strum by high-pcrformante liquid chromatography has been developed. The analysis uses ullraviolct detection at 254 nm, and a 5 jtm reversed-phase column with a mobile phase of water-tricthylaminc-acctonitrilc-PIG-B8 reagent. Scrum extraction is performed with dichloromethane and 1 &f sodium hydroxide. p-Chlorodisopyramide is used as internal standard.
INTRODUCTION
Disopyramide is a widely used antiarrhythmic drug with class Ia activity, according to the Vaughan and Williams classification [1, 2] . In clinical trials it has been shown to be effective for treatment of atria1 fibrillation [3-S] and ventricular arrhythmias [4,6-l 11 . Although successful treatment of arrhythmias may not be directly correlated with serum levels, determination of serum levels is helpful to check compliance, especially in out-patient treatment, when side-e-Sects occur, and to exclude sub-optimal dosing, especially in oral therapy;
Serum concentrations of mono-N-desalkylated disopyramide (MND) reach cn. 30% of the disopyramide serum concentration during long-term oral therapy [12] and are increased by enzyme induction or renal failure [12, 13] . As MND is reported to have a lower antiarrhythmic activity but marked anticholirergic activity [13] , determination of MND seems to be useful, when anticholinergic side- A 2.0-ml volume of dichloromethane, 110 ml of serum, 100 ~1 of 1 M sodium hydroxide and 100 p.ri of the stock solution of the internal standard were introduced into a glass centrifuge tube, obtained from KBstner (Tubingen, Germany). The tube was stoppered with a plastic stopper, obtained from Sarstedt (Ntimbrecht, Germany), vortex-mixed for 60 s and centrifuged at 3600 g for 10 min. Subsequently the aqueous phase was discarded, and 1.0 ml of the dichloromethane phase was transferred to a clean glass tube and evaporated to dryness at room temperature under nitrogen. The residue was dissolved in 500 ,ul of 0.01 M hydrochloric acid, and 200 ,~l were injected into the column.
Standards
The ktock standard solutions were prepared by dissolving 3 mg of disopyramide, 3 mg of MND and 3 mg of p-chlorodisopyramide each in 100 ml of 0.01 M hydrochloric acid. In this way stock standard solutions, containing 30 pg/ml of each substance, were obtained, which proved to be stable for at least two months at 4°C. A working standard solution was prepared by combining 100 ~1 of each stock standard solution with 700 ~1 of 0.01 A4 hydrochloric acid. This working standard solution contained disopyramide, MND and the internal standard pchlorodisopyramide in concentrations of 3 /cg/ml each.
.
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Cetection wavelength
To find the optimal detection wavelength, UV absorption spectral analysis was performed over a wavelength range of 200-500 nm with the stock standard solutions of disopyramide and MND. Both substances showed a maximum of absorption at 2% nm.
Chromatograpitic conditions
The analysis was performed at room temperature using a Shandon ODS reversed-phase column (125 mm x 4.6 mm I.D., particle size 5 pm). The mobile phase consisted of 70% A (974 ml of water, 25 ml of PIC-BS reagent and 1 ml of triethylamine) and 30% B (acetonitrile). The concentration of I-octanesulphonic acid in part A of the mobile phase was 0.0125 h$. The flow-rate was 1 .O ml/min. The column effluent was monitored at 254 nm, Itsing a detector or range of 0.02 a.u.f.s. and a chart-speed of 0.5 cm/min. The injection volume ~2s 200 $.
Louver limit of detectiolt
The lower limit of detection was determined by diluting the working standard solution to concentrations of 1 .O, 0.5, 0.25,O. 1 and 0.05 pg/ml for disopyrLmide, MND and the internal standard. A signal-to-noise ratio of 3: 1 was set as the limit for detection of a peak.
Recovery rntes
Recovery rates were determined by comparing the peak areas of disopyramide, MND and the internal standard? obtained by analysing ten spiked serum samples (10G ~1 of each stock solution, added to 1 .O ml of normal pool serum), with peak areas obtained by direct injection of the standard working solution.
The technical error was determined by injecting the same sample ten times. Ten peak areas were compared and given as percentage values.
Limarity test
The linear relationship of peak areas to substance concentrations was demonstrated by analysing five standard so!utions, containing concentrations of 6.00, 3.00, 1.50, 0.75 and 0.375 pg/ml disopyramide, MND and the internal standard. Peak areas were plotted versus substance concentration< in orthogonal scaies and resulted in a linear curve.
The same procedure was performed for spiked serum samples, containing similar concentrations of disopyramide, MND and the internal standard.
Quant#kntiorz
Because a linear relationship between substance concentrations and peak areas was obtained, no daily calibration graph was necessary. Calculation was per-formed by comparing peak arcas of the standard working solution (analysed before every serum sample) to peak areas of serum samples, obtained by the described extraction procedure.
Blood was taken by venous puncture of a gubital vein, and serum was obtained by centrifugation at 900 g, avoiding haemolysis. Twenty-two serum samples from normal volunteers (twelve male, ten female) were pooled (normal pool). This drug-free no1 ma1 pool serum was used for blank chromatograms and for preparing spiked serum samples for the linearity test and for the recovery rate.
Eleven undiluted serum samples from patients treated with cardiovascular drugs, such as acetylsalicylic acid, heparin, phenprocoumone, nifedipine, diltiazem, verapamil, nitrendipine, betaxolol, metoprolol, isosorbide mononitrate, furosemidc, xipamide, spironolactone, hydrochlorothiazide, triamterene, allopurinol, bezciibrate, enalapril, captopril, digitoxin, metildigoxin, digoxin and diazepam, were analysed with the above described assay.
Fifteen serum samples from fifteen patic-:ats (three female, twelve male) undergoing chronic oral therapy (;lt least five days) with two 250-mg sustained-release tablets per day were analysed individually. Samples were taken as trough levels at 8:00 a.m. before the morning dose was taken. None of the patients had signs of congestive heart failure or kidney or liver dysfunction.
RESULTS
-4 linear relationship between the concentration oft'--a~~ suI~?ances and the peak areas for the standards, as well as for spiked serum samples, couId be demonstrated. The mean recovery rates were 94.5 f 5.7% for disopyramide (coefficient of variation, C.V. 6.030/b), 96.8 =t 2.2% for MND (C.V. 2.27%) and 97.9 f 2.8% for the internal standard (C.V. 2.86%).
The inter-assay C.V. (II = 10) were 6.0% for disopyramide and 2.3% for MND. The intra-assay C.V. (12 = 10) were 2.7% for disopyramide and 1.4% for MND. The technical error of the apparatus was less than 1% for disopyramide, MND and the internal standard. Disopyramide serum levels were 2.00 f 0.85 /lg/ml and MND levels were 0.60 f 0.33 Gg/ml, in fifteen patients taking 270 f 14 mg of disopyramide per square mctre of body surface orally (data given as mean f S.D.).
None of the above-mentioned drugs showed interference with the determination of discpyramide. There was no significant correlation either between dosage per body surface area or serum concentrations of disopyramide or MND in fifteen patients during chronic oral drug treatment. 
DISCUSSION
Gas chromatographic methods have proved to be highly.specific and sensitive for measuring serum levels of disapyramide [14-I 91, but have the disadvantage that the samples have to be derivatized and therefore the analyses are more time-consuming.
Immunological methods for measuring disopyramide levels with monocIona1 antibodies have been developed [20-231 but quantification of MND is not possible.
A variety of HPLC methods with UV detection for determination of disopyramide have been published [16, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Some give essenriaiiy lower analytical recovery rates for disopyramide or its main metabolite MND [26, 29, 30] . Without an internal standardization some methods need a time-consuming calibration graph to be prepared before every analysis [27, 28] . Ilett et al. [16] used organic liquid extraction with dichloromethane, but quantitative determination of MND and analytical recovery rates were not described in this publication. The method published by Angelo ei crl. 1241 gives excellent recovery rates for disopyramide and MND, but their use of dimethyl ether for extraction has several disadvantages (working with an inflammable, explosive and narcotic substance in closed rooms). Methods published by Radwan ei ai. [31] , Sweezy and Ponzo [33] and Broussard and Frings [25] do not aliow determination of MND. Wang et al. [33] used a silica gel column and an aqueous mobile phase, consisting of dibasic ammonium phosphate. This method gives high recovery rates for disopyramide and MND, btit is rather expensive, because HzS04, the solvent for probe injection, quickly destroys the analytical column, despite the presence of a guard co!umn .
The method described in this paper for determination of disopyramide and its main metabolite MND in serum is easy to handle, rapid to perform and inexpensive. Nearly complete analytical recovery of disopyramide and MND is obtained. The range of detection (0. I-6.0 irg/ml) is sufficient for monitoring subtherapeutic levels (e.g. single-dose studies) as well as toxic levels.
